FR18C1036I2 - Derives de dioxa-bicyclo[3.2.1.]octane-2,3,4-triol - Google Patents

Derives de dioxa-bicyclo[3.2.1.]octane-2,3,4-triol

Info

Publication number
FR18C1036I2
FR18C1036I2 FR18C1036C FR18C1036C FR18C1036I2 FR 18C1036 I2 FR18C1036 I2 FR 18C1036I2 FR 18C1036 C FR18C1036 C FR 18C1036C FR 18C1036 C FR18C1036 C FR 18C1036C FR 18C1036 I2 FR18C1036 I2 FR 18C1036I2
Authority
FR
France
Prior art keywords
dioxa
bicyclo
octane
triol derivatives
triol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR18C1036C
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Inc
Original Assignee
Pfizer Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41208284&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR18C1036(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Inc filed Critical Pfizer Inc
Publication of FR18C1036I1 publication Critical patent/FR18C1036I1/fr
Application granted granted Critical
Publication of FR18C1036I2 publication Critical patent/FR18C1036I2/fr
Active legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H9/00—Compounds containing a hetero ring sharing at least two hetero atoms with a saccharide radical
    • C07H9/02—Compounds containing a hetero ring sharing at least two hetero atoms with a saccharide radical the hetero ring containing only oxygen as ring hetero atoms
    • C07H9/04—Cyclic acetals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
FR18C1036C 2008-08-28 2018-08-24 Derives de dioxa-bicyclo[3.2.1.]octane-2,3,4-triol Active FR18C1036I2 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US9247008P 2008-08-28 2008-08-28
US22721209P 2009-07-21 2009-07-21
PCT/IB2009/053626 WO2010023594A1 (fr) 2008-08-28 2009-08-17 Dérivés de dioxa-bicyclo[3.2.1.]octane-2,3,4-triol

Publications (2)

Publication Number Publication Date
FR18C1036I1 FR18C1036I1 (fr) 2018-10-05
FR18C1036I2 true FR18C1036I2 (fr) 2020-07-24

Family

ID=41208284

Family Applications (1)

Application Number Title Priority Date Filing Date
FR18C1036C Active FR18C1036I2 (fr) 2008-08-28 2018-08-24 Derives de dioxa-bicyclo[3.2.1.]octane-2,3,4-triol

Country Status (47)

Country Link
US (1) US8080580B2 (fr)
EP (1) EP2334687B9 (fr)
JP (1) JP4825322B1 (fr)
KR (2) KR101446454B1 (fr)
CN (2) CN103497199B (fr)
AP (1) AP2728A (fr)
AR (1) AR073138A1 (fr)
AT (1) ATE540040T1 (fr)
AU (1) AU2009286380B2 (fr)
BR (1) BRPI0918841B8 (fr)
CA (1) CA2733795C (fr)
CL (1) CL2011000394A1 (fr)
CO (1) CO6341636A2 (fr)
CR (1) CR20110077A (fr)
CY (2) CY1112497T1 (fr)
DK (1) DK2334687T5 (fr)
DO (1) DOP2011000058A (fr)
EA (1) EA018492B1 (fr)
EC (1) ECSP11010854A (fr)
ES (1) ES2380408T3 (fr)
FR (1) FR18C1036I2 (fr)
GE (1) GEP20135803B (fr)
HK (2) HK1156616A1 (fr)
HN (1) HN2009001652A (fr)
HR (1) HRP20120104T1 (fr)
HU (1) HUS1800031I1 (fr)
IL (2) IL211226A (fr)
LT (1) LTC2334687I2 (fr)
MA (1) MA32590B1 (fr)
ME (1) ME01285A (fr)
MX (1) MX2011002166A (fr)
MY (1) MY155418A (fr)
NI (1) NI201100043A (fr)
NL (1) NL300943I2 (fr)
NO (1) NO2018019I2 (fr)
NZ (1) NZ591027A (fr)
PA (1) PA8840801A1 (fr)
PE (1) PE20110288A1 (fr)
PL (1) PL2334687T3 (fr)
PT (1) PT2334687E (fr)
RS (1) RS52236B (fr)
SI (1) SI2334687T1 (fr)
SV (1) SV2011003842A (fr)
TW (1) TWI387598B (fr)
UY (1) UY32073A (fr)
WO (1) WO2010023594A1 (fr)
ZA (1) ZA201101341B (fr)

Families Citing this family (113)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0916769A2 (pt) 2008-07-15 2017-09-26 Theracos Inc derivados de benzilbenzeno deuterados e métodos de uso
JP5696156B2 (ja) 2009-11-02 2015-04-08 ファイザー・インク ジオキサ−ビシクロ［３．２．１］オクタン−２，３，４−トリオール誘導体
SI2547679T1 (sl) 2010-03-19 2015-12-31 Pfizer Inc. Derivati 2,3 dihidro-1H-inden-1-il-2,7-diazaspiro(3.6)nonana in njihova uporaba kot antagonisti ali inverzni agonisti grelinskega receptorja
CN102372722A (zh) * 2010-08-10 2012-03-14 江苏恒瑞医药股份有限公司 C-芳基葡萄糖苷衍生物、其制备方法及其在医药上的应用
WO2012041898A1 (fr) 2010-09-29 2012-04-05 Celon Pharma Sp. Z O.O. Combinaison de l'inhibiteur de sglt2 et d'un composé de sucre pour le traitement du diabète
NZ609527A (en) 2010-10-29 2014-03-28 Pfizer N1/n2-lactam acetyl-coa carboxylase inhibitors
WO2012109996A1 (fr) * 2011-02-18 2012-08-23 上海璎黎科技有限公司 Composé aryl glycoside, son procédé de préparation et d'utilisation
EP2680874A2 (fr) 2011-03-04 2014-01-08 Pfizer Inc Peptides de type edn3 et utilisations associées
CN103492388A (zh) 2011-04-22 2014-01-01 辉瑞大药厂 用作乙酰辅酶a羧化酶抑制剂类的吡唑并螺酮衍生物
BR112013031032A2 (pt) 2011-06-03 2016-11-29 Boehringer Ingelheim Int inibidores de sglt-2 para o tratamento de distúrbios metabólicos em pacientes tratados com agentes neurolépticos
JP2014517032A (ja) * 2011-06-13 2014-07-17 パナセア バイオテック リミテッド 新規のｓｇｌｔ阻害剤
TWI510491B (zh) * 2011-06-30 2015-12-01 Shanghai Hengrui Pharm Co Ltd Ｃ－芳基葡萄糖苷衍生物、其製備方法及其在醫藥上的應用
WO2013011402A1 (fr) 2011-07-15 2013-01-24 Pfizer Inc. Modulateurs de gpr 119
WO2013014569A1 (fr) 2011-07-22 2013-01-31 Pfizer Inc. Modulateurs des récepteurs de quinolinylglucagon
EP2751116B1 (fr) 2011-08-31 2016-10-12 Pfizer Inc Hexahydropyrano[3,4-d][1,3]thiazine-2-amines
US9018249B2 (en) 2011-09-13 2015-04-28 Panacea Biotec Limited SGLT inhibitors
WO2013068439A1 (fr) 2011-11-09 2013-05-16 Intervet International B.V. Composés 4-amino-5-oxo-7,8-dihydropyrimido[5, 4 -f] [1, 4] oxazépine comme inhibiteurs de dgat1
CA2853024C (fr) 2011-11-11 2017-08-22 Pfizer Inc. 2-thiopyrimidinones
CA2869587A1 (fr) 2012-04-06 2013-10-10 Pfizer Inc. Inhibiteurs de diacylglycerol acyltransferase 2
US9193751B2 (en) 2012-04-10 2015-11-24 Theracos, Inc. Process for the preparation of benzylbenzene SGLT2 inhibitors
US8889730B2 (en) 2012-04-10 2014-11-18 Pfizer Inc. Indole and indazole compounds that activate AMPK
JP6110937B2 (ja) 2012-05-04 2017-04-05 ファイザー・インク ＡＰＰ、ＢＡＣＥ１、およびＢＡＣＥ２の阻害剤としての複素環式置換ヘキサヒドロピラノ［３，４−ｄ］［１，３］チアジン−２−アミン化合物
CN103570657A (zh) * 2012-07-19 2014-02-12 天津药物研究院 一类含偕二甲基的苯基c-葡萄糖苷衍生物、其制备方法和用途
US9145434B2 (en) 2012-07-26 2015-09-29 Boehringer Ingelheim International Gmbh Crystalline complex of 1-cyano-2-(4-cyclopropyl-benzyl)-4-(ss-d-glucopyranos-1-yl)-benzene, methods for its preparation and the use thereof for preparing medicaments
JP2015529239A (ja) 2012-09-20 2015-10-05 ファイザー・インク アルキル置換ヘキサヒドロピラノ［３，４−ｄ］［１，３］チアジン−２−アミン化合物
CN103772449B (zh) * 2012-10-26 2017-12-26 上海阳帆医药科技有限公司 C‑芳基葡萄糖苷衍生物及其制备方法与用途
WO2014086099A1 (fr) * 2012-12-05 2014-06-12 广东东阳光药业有限公司 Dérivé glucopyranosylique, son procédé de préparation et son utilisation médicale
EP2931731A1 (fr) 2012-12-11 2015-10-21 Pfizer Inc. Composés d'hexahydropyrano [3,4-d][1,3]thiazin-2-amine en tant qu'inhibiteurs de bace1
WO2014094544A1 (fr) * 2012-12-17 2014-06-26 天津药物研究院 Dérivé de phényl-c-glucoside contenant une structure de désoxyglucose, procédé de préparation et utilisation de celui-ci
EP2935282A1 (fr) 2012-12-19 2015-10-28 Pfizer Inc. Composés hexahydropyrano[3,4-d][1,3]thiazin-2-amine substitués carbocycliques et hétérocycliques
WO2014125394A1 (fr) 2013-02-13 2014-08-21 Pfizer Inc. Composés hexahydropyrano [3,4-d][1,3] thiazin-2-amine substitués par un hétéroaryle
US9233981B1 (en) 2013-02-15 2016-01-12 Pfizer Inc. Substituted phenyl hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds
CN104045513A (zh) * 2013-03-14 2014-09-17 爱康药业有限公司 4-取代-1-氯-2-(4-氟苄基)苯及其制备方法和作为中间体在制备抗ii型糖尿病药物中的应用
EP2968375B1 (fr) * 2013-03-14 2019-06-12 MSD International GmbH Procédés de préparation d'inhibiteurs de sglt2
EP4245765A3 (fr) 2013-04-04 2024-03-20 Boehringer Ingelheim Vetmedica GmbH Traitement de troubles metaboliques chez des animaux equins
CN104619713B (zh) * 2013-05-24 2017-06-16 四川海思科制药有限公司 氧杂双环衍生物、制备方法及其应用
WO2015027963A1 (fr) * 2013-09-02 2015-03-05 四川海思科制药有限公司 Dérivé à noyau aromatique, composition pharmaceutique et utilisation associée
EP2895490B1 (fr) * 2013-09-27 2016-10-19 Sunshine Lake Pharma Co., Ltd. Dérivés de glucopyranosyl et leurs utilisations en médecine
JP6348582B2 (ja) 2013-10-09 2018-06-27 ファイザー・インク プロスタグランジンｅｐ３受容体の拮抗薬
WO2015051484A1 (fr) 2013-10-12 2015-04-16 Theracos, Inc. Préparation de dérivés d'hydroxy-benzylbenzène
CN105828815B (zh) 2013-12-17 2020-03-27 勃林格殷格翰动物保健有限公司 猫科动物中代谢紊乱的治疗
PL3485890T3 (pl) 2014-01-23 2023-08-28 Boehringer Ingelheim Vetmedica Gmbh Inhibitory SGLT2 do leczenia zaburzeń metabolicznych u zwierząt psowatych
EA032356B1 (ru) 2014-03-17 2019-05-31 Пфайзер Инк. Ингибиторы диацилглицеринацилтрансферазы 2 для применения в лечении метаболических и связанных с метаболизмом расстройств
DK3125882T3 (da) * 2014-04-01 2020-06-29 Boehringer Ingelheim Vetmedica Gmbh Behandling af metabolske lidelser i hestedyr
LT3536685T (lt) 2014-04-04 2022-04-25 Pfizer Inc. Biciklinio sulieto heteroarilo arba arilo junginiai ir jų naudojimas kaip irak4 inhibitorių
MD20160105A2 (ro) 2014-04-10 2017-03-31 Pfizer Inc. 2-Amino-6-metil-4,4a,5,6-tetrahidropirano[3,4-d][1,3]tiazin-8a(8H)-il-1,3-tiazol-4-il amide
JP6193513B2 (ja) * 2014-05-19 2017-09-06 ファイザー・インク Ａｓｇｐｒ標的化剤としての置換６，８−ジオキサビシクロ［３．２．１］オクタン−２，３−ジオール化合物
CN104017031A (zh) * 2014-06-21 2014-09-03 李友香 降血糖药物和组合物
CN104031098A (zh) * 2014-06-21 2014-09-10 李友香 降糖药物
EP3197429A1 (fr) 2014-09-25 2017-08-02 Boehringer Ingelheim Vetmedica GmbH Polythérapie avec des inhibiteurs de sglt2 et des agonistes de la dopamine utilisée pour la prévention des troubles métaboliques chez des équidés
CN105461762B (zh) * 2014-09-27 2018-12-04 广东东阳光药业有限公司 吡喃葡萄糖基衍生物及其在医药上的应用
CA2961819C (fr) * 2014-09-30 2022-11-08 Jiangsu Hengrui Medicine Co., Ltd. Compose l-proline d'un inhibiteur du cotransporteur sodium-glucose de type 2, ainsi que monohydrate et cristal du compose l-proline
US10285973B2 (en) * 2014-11-10 2019-05-14 Merck Sharp & Dohme Corp. SGLT-2 inhibitors for treating metabolic disorders in patients with renal impairment or chronic kidney disease
WO2016092413A1 (fr) 2014-12-10 2016-06-16 Pfizer Inc. Composés indoliques et indazoliques qui activent l'ampk
EP3237401B1 (fr) 2014-12-22 2019-03-06 Pfizer Inc Antagonistes de récepteur ep3 de prostaglandine
EP3292109A1 (fr) 2015-05-05 2018-03-14 Pfizer Inc 2-thiopyrimidinones
EP3303345A4 (fr) 2015-05-25 2019-01-30 Sun Pharmaceutical Industries Ltd Co-cristaux d'ertuglifozine et procédé pour les préparer
EP3303303A1 (fr) 2015-05-29 2018-04-11 Pfizer Inc Nouveaux composés hétérocycliques utilisés en tant qu'inhibiteurs de l'enzyme vanine-1
CN107787322B (zh) 2015-06-17 2023-07-07 辉瑞大药厂 三环化合物以及它们作为磷酸二酯酶抑制剂的用途
WO2016203335A1 (fr) 2015-06-18 2016-12-22 Pfizer Inc. Nouvelles pyrido [2,3-b] pyrazinones utilisées en tant qu'inhibiteurs de bromodomaines de la famille bet
CA2995153A1 (fr) 2015-08-13 2017-02-16 Pfizer Inc. Composes aryle ou heteroaryle condenses bicycliques
US10220017B2 (en) 2015-08-27 2019-03-05 Boehringer Ingelheim Vetmedica Gmbh Liquid pharmaceutical compositions comprising SGLT-2 inhibitors
PT3341367T (pt) 2015-08-27 2021-04-19 Pfizer Compostos de arilo ou heteroarilo bicíclicos fusionados como moduladores de irak4
WO2017037567A1 (fr) 2015-09-03 2017-03-09 Pfizer Inc. Régulateurs de la frataxine
WO2017051276A1 (fr) 2015-09-24 2017-03-30 Pfizer Inc. N-[2-(2-amino-6,6-disubstitués-4,4a,5,6-tétrahydropyrano[3,4-d][1,3]thiazin-8a(8h)-yl)-1,3-thiazol-4-yl]amides
EP3353182A1 (fr) 2015-09-24 2018-08-01 Pfizer Inc Dérivés de tétrahydropyrano[3,4-d][1,3]oxazine et leur utilisation en tant qu'inhibiteurs de bace
JP2018534251A (ja) 2015-09-24 2018-11-22 ファイザー・インク Ｂａｃｅ阻害剤として有用なｎ−［２−（３−アミノ−２，５−ジメチル−１，１−ジオキシド−５，６−ジヒドロ−２ｈ−１，２，４−チアジアジン−５−イル）−１，３−チアゾール−４−イル］アミド
SI3397631T1 (sl) 2015-12-29 2022-01-31 Pfizer Inc. Substituirani 3-azabiciklo(3.1.0)heksani kot zaviralci ketoheksokinaze
TR201810664T1 (tr) 2016-01-04 2018-08-27 Je Il Pharmaceutical Co Ltd Kaynaşık fenil halkaya sahip C-glikozid türevleri veya bunların farmasötik olarak kabul edilebilen tuzları, bunları hazırlamak için usul ve bunları içeren farmasötik bileşim.
CN105646604A (zh) * 2016-03-01 2016-06-08 孙霖 埃格列净晶型b及制备方法
CN105646603A (zh) * 2016-03-01 2016-06-08 孙霖 埃格列净晶型a及制备方法
EP3735975A1 (fr) 2016-03-11 2020-11-11 Merck Sharp & Dohme Corp. Procédé de traitement ou de réduction du risque d'événements cardiovasculaires et de maladies associées au moyen d'inhibiteur de sglt-2
AU2017296338A1 (en) 2016-07-14 2019-01-03 Pfizer Inc. Novel pyrimidine carboxamides as inhibitors of vanin-1 enzyme
WO2018011721A1 (fr) * 2016-07-15 2018-01-18 Granules India Limited Nouvelles formes polymorphes de ((1s,2s,3s,4r,5s))-2,3,4-(tris-benzyloxy)-5-(4-chloro-3-(4-éthoxy-benzyl)phényl)-6,8-dioxa-bicyclo[3.2.1]oct-1-yl-méthanol
AR109179A1 (es) 2016-08-19 2018-11-07 Pfizer Inhibidores de diacilglicerol aciltransferasa 2
EA201990951A1 (ru) 2016-10-19 2019-11-29 Комбинации, содержащие ssao/vap-1 ингибитор и sglt2-ингибитор, и их применение
CN107382952B (zh) * 2017-07-13 2020-02-28 杭州科巢生物科技有限公司 埃格列净的制备方法及其中间体
CN107898764A (zh) * 2017-12-12 2018-04-13 威海贯标信息科技有限公司 一种埃格列净组合物
WO2019133445A1 (fr) 2017-12-28 2019-07-04 Inception Ibd, Inc. Aminothiazoles utilisés en tant qu'inhibiteurs de vanin-1
CN107857768A (zh) * 2018-01-04 2018-03-30 威海贯标信息科技有限公司 一种埃格列净新晶型
CN111566112B (zh) * 2018-03-06 2022-02-15 广东东阳光药业有限公司 埃格列净的晶型及其制备方法
EP3781166A1 (fr) 2018-04-17 2021-02-24 Boehringer Ingelheim International GmbH Composition pharmaceutique, méthodes de traitement et utilisations associées
WO2019202149A1 (fr) 2018-04-19 2019-10-24 Université Catholique de Louvain Inhibiteurs de sglt2 pour le traitement de la neutropénie
WO2020001812A1 (fr) 2018-06-25 2020-01-02 Pharmathen S.A. Nouveau procédé de préparation d'inhibiteurs de sglt-2
WO2020026273A1 (fr) * 2018-07-31 2020-02-06 Msn Laboratories Private Limited, R&D Center Formes solides de base libre d'ertugliflozine et dispersions à l'état solide comprenant de l'acide ertugliflozin l-pyroglutamique
WO2020039394A1 (fr) 2018-08-24 2020-02-27 Novartis Ag Nouvelles combinaisons de médicaments
US11254660B2 (en) 2018-08-31 2022-02-22 Pfizer Inc. Combinations for treatment of NASH/NAFLD and related diseases
WO2020102575A1 (fr) 2018-11-16 2020-05-22 Inception Ibd, Inc. Aminothiazoles hétérocycliques et leurs utilisations
EP3972596A1 (fr) 2019-05-20 2022-03-30 Pfizer Inc. Combinaisons comprenant du benzodioxol en tant qu'agonistes de glp-1r destinées à être utilisées dans le traitement de la nash/nafld et de maladies associées
US20220363673A1 (en) 2019-06-28 2022-11-17 Pfizer Inc. 5-(Thiophen-2-YL)-1 H-Tetrazole Derivative as BCKDK Inhibitors Useful for Treating Various Diseases
TW202115086A (zh) 2019-06-28 2021-04-16 美商輝瑞大藥廠 Bckdk抑制劑
WO2021004498A1 (fr) * 2019-07-10 2021-01-14 Sunshine Lake Pharma Co., Ltd. Dérivés de glucopyranosyle et leurs utilisations
TWI771766B (zh) 2019-10-04 2022-07-21 美商輝瑞股份有限公司 二醯基甘油醯基轉移酶２ 抑制劑
WO2021105152A1 (fr) 2019-11-28 2021-06-03 Boehringer Ingelheim Vetmedica Gmbh Utilisation d'inhibiteurs de sglt-2 dans le séchage de mammifères non humains
WO2021121270A1 (fr) * 2019-12-19 2021-06-24 上海研健新药研发有限公司 Procédé de purification d'un inhibiteur des sglt et utilisation associée
JP7423800B2 (ja) 2020-02-17 2024-01-29 ベーリンガー インゲルハイム フェトメディカ ゲーエムベーハー ネコにおける心臓疾患の予防および／または治療のためのｓｇｌｔ－２阻害剤の使用
JP2022058085A (ja) 2020-02-24 2022-04-11 ファイザー・インク ジアシルグリセロールアシルトランスフェラーゼ２阻害剤とアセチル－ＣｏＡカルボキシラーゼ阻害剤との組合せ
EP4138826A1 (fr) 2020-04-22 2023-03-01 Bayer Aktiengesellschaft Combinaison de finérénone et d'un inhibiteur de sglt2 pour le traitement et/ou la prévention de maladies cardiovasculaires et/ou rénales
PE20231215A1 (es) 2020-06-09 2023-08-17 Pfizer Compuestos espiro como antagonistas del receptor de melanocortina 4 y usos de los mismos
WO2021260498A1 (fr) * 2020-06-22 2021-12-30 Aurobindo Pharma Limited Procédé de purification amélioré pour la préparation de co-cristal d'acide ertugliflozine et d'ertugliflozin l-pyroglutamique
CN114195748B (zh) * 2020-09-17 2023-11-14 上海森辉医药有限公司 一种钠-葡萄糖协同转运蛋白2抑制剂的制备方法
KR20240041966A (ko) 2021-07-28 2024-04-01 베링거잉겔하임베트메디카게엠베하 고양이를 제외한 비인간 포유류, 특히 개에서 심장 질환의 예방 및/또는 치료를 위한 sglt-2 억제제의 용도
WO2023006745A1 (fr) 2021-07-28 2023-02-02 Boehringer Ingelheim Vetmedica Gmbh Utilisation d'inhibiteurs de sglt-2 pour la prévention et/ou le traitement de l'hypertension chez des mammifères non humains
AU2022318037A1 (en) 2021-07-28 2024-02-22 Boehringer Ingelheim Vetmedica Gmbh Use of sglt-2 inhibitors for the prevention and/or treatment of renal diseases in non-human mammals
WO2023026180A1 (fr) 2021-08-26 2023-03-02 Pfizer Inc. Forme amorphe de (s)-2-(5-((3-éthoxypyridin-2-yl)oxy)pyridin-3-yl)-n-(tétrahydrofuran-3-yl)pyrimidine-5-carboxamide
KR20230060921A (ko) 2021-10-28 2023-05-08 유니셀랩 주식회사 에르투글리플로진의 신규 전구체
TW202337429A (zh) 2021-12-01 2023-10-01 美商輝瑞股份有限公司 支鏈酮酸脫氫酶激酶（ｂｃｋｄｋ）抑制劑及／或降解劑
WO2023105387A1 (fr) 2021-12-06 2023-06-15 Pfizer Inc. Antagonistes du récepteur 4 de la mélanocortine et leurs utilisations
WO2023169456A1 (fr) 2022-03-09 2023-09-14 Gasherbrum Bio , Inc. Agonistes hétérocycliques de glp-1
WO2023198140A1 (fr) 2022-04-14 2023-10-19 Gasherbrum Bio, Inc. Agonistes hétérocycliques de glp-1
US20230381101A1 (en) 2022-05-25 2023-11-30 Boehringer Ingelheim Vetmedica Gmbh Aqueous pharmaceutical compositions comprising sglt-2 inhibitors
WO2024075051A1 (fr) 2022-10-07 2024-04-11 Pfizer Inc. Inhibiteurs et/ou agents de dégradation de hsd17b13
WO2024084360A1 (fr) 2022-10-18 2024-04-25 Pfizer Inc. Modificateurs de la proteine 3 contenant le domaine phospholipase de type patatine (pnpla3)

Family Cites Families (146)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US486299A (en) * 1892-11-15 John k
US560230A (en) * 1896-05-19 powers
US247705A (en) * 1881-09-27 William a
US838442A (en) * 1906-05-31 1906-12-11 Oscar Mietens Compressed-air railway-train brake.
FR1499439A (fr) * 1966-09-16 1967-10-27 Electrochimie Soc Nouveau polyol et procédé pour sa préparation
JPS5373598A (en) * 1976-12-11 1978-06-30 Teikoku Chem Ind Corp Ltd Saccharide derivatives and process for thir preparation
JPS5911600B2 (ja) * 1981-04-30 1984-03-16 理化学研究所 ３−アジド−１，６−アンヒドロ−３−デオキシ−２，４−ジ−Ｏ−ベンジル−β−Ｄ−グルコピラノ−ス及びその製造法
NZ214774A (en) 1986-01-08 1989-10-27 Nz Scientific & Ind Res Herbicidal and/or plant growth regulatory compositions based on 1,6-anhydro-beta-hexopyranose derivatives and certain of these derivatives
US5041541A (en) 1988-05-05 1991-08-20 The Procter & Gamble Company Functional sugar substituted with reduced calories
CN1020944C (zh) 1990-01-30 1993-05-26 阿图尔-费希尔股份公司费希尔厂 紧固件
CA2079544A1 (fr) 1991-10-04 1993-04-05 Adam Weislaw Mazur Composes permettant de faire baisser le taux de cholesterol
DE4400464A1 (de) * 1994-01-11 1995-07-13 Bayer Ag Endoparasitizide Mittel
PT850948E (pt) 1996-12-26 2002-08-30 Tanabe Seiyaku Co Derivados propiofenona e processo para a preparacao dos mesmos
US6486299B1 (en) 1998-09-28 2002-11-26 Curagen Corporation Genes and proteins predictive and therapeutic for stroke, hypertension, diabetes and obesity
US6069238A (en) 1998-09-30 2000-05-30 Eli Lilly And Company Spirocyclic C-glycosides
ATE264337T1 (de) 1999-08-31 2004-04-15 Kissei Pharmaceutical Glucopyranosyloxypyrazol-derivate, diese enthaltende arzneimittel und zwischenprodukte zu deren herstellung
US6515117B2 (en) 1999-10-12 2003-02-04 Bristol-Myers Squibb Company C-aryl glucoside SGLT2 inhibitors and method
PH12000002657B1 (en) 1999-10-12 2006-02-21 Bristol Myers Squibb Co C-aryl glucoside SGLT2 inhibitors
WO2001042469A1 (fr) 1999-12-10 2001-06-14 Lexicon Genetics Incorporated Nouvelle proteine transporteuse humaine et polynucleotides codant celle-ci
US6627611B2 (en) 2000-02-02 2003-09-30 Kotobuki Pharmaceutical Co Ltd C-glycosides and preparation of thereof as antidiabetic agents
DE10006887A1 (de) 2000-02-16 2001-09-06 Hermann Koepsell Verbindungen, die die Aktivität oder die Konzentration des Regulatorproteins RS1 verändern
DE10008128A1 (de) 2000-02-22 2001-08-23 Bayer Ag Endoparasitizide Mittel
NZ521369A (en) 2000-03-17 2004-07-30 Kissei Pharmaceutical Glucopyranosyloxybenzylbenzene derivatives, medicinal compositions containing the same and intermediates for the preparation of the derivatives
US6683056B2 (en) 2000-03-30 2004-01-27 Bristol-Myers Squibb Company O-aryl glucoside SGLT2 inhibitors and method
US6555519B2 (en) 2000-03-30 2003-04-29 Bristol-Myers Squibb Company O-glucosylated benzamide SGLT2 inhibitors and method
CZ303544B6 (cs) 2000-09-29 2012-11-28 Kissei Pharmaceutical Co., Ltd. Glukopyranosyloxybenzylbenzenový derivát a farmaceutická kompozice s jeho obsahem
AU2002210990A1 (en) 2000-11-02 2002-05-15 Ajinomoto Co. Inc. Novel pyrazole derivatives and diabetes remedies containing the same
CA2429833A1 (fr) 2000-11-30 2002-06-06 Kissei Pharmaceutical Co., Ltd. Derives de glucopyranosyloxybenzylbenzene, compositions medicinales contenant ces derives et produits intermediaires obtenus lors de l'elaboration de ces compositions
US20020081678A1 (en) 2000-12-11 2002-06-27 Gennady Merkulov Isolated nucleic acid molecules encoding human transporter proteins, and uses thereof
US7247705B2 (en) 2000-12-28 2007-07-24 Takeda Pharmaceutical Company Limited Proteins having glucose transporter activity
PL209375B1 (pl) 2000-12-28 2011-08-31 Kissei Pharmaceutical Pochodne glukopiranozyloksypirazolu, kompozycja farmaceutyczna zawierająca takie pochodne i zastosowanie tych pochodnych do wytwarzania kompozycji farmaceutycznej
TWI255817B (en) 2001-02-14 2006-06-01 Kissei Pharmaceutical Glucopyranosyloxybenzylbenzene derivatives and medicinal use thereof
EP1364957B1 (fr) 2001-02-26 2008-12-31 Kissei Pharmaceutical Co., Ltd. Derives de glycopyranosyloxypyrazole et utilisation medicinale de ceux-ci
US7294618B2 (en) 2001-02-27 2007-11-13 Kissei Pharmaceutical Co., Ltd. Glucopyranosyloxypyrazole derivatives and medicinal use thereof
US6936590B2 (en) 2001-03-13 2005-08-30 Bristol Myers Squibb Company C-aryl glucoside SGLT2 inhibitors and method
EP1419251A4 (fr) 2001-03-27 2005-05-04 Applera Corp Proteines transporteur humaines isolees, molecules d'acide nucleique codant ces proteines transporteur humaines et utilisations de ces dernieres
CA2442917C (fr) 2001-04-04 2011-02-01 Ortho-Mcneil Pharmaceutical, Inc. Polytherapie comprenant des inhibiteurs de reabsorption du glucose et des modulateurs ppar
DE60233655D1 (de) 2001-04-04 2009-10-22 Ortho Mcneil Janssen Pharm R und retinoid x rezeptorenmodulatoren
WO2002083857A2 (fr) 2001-04-10 2002-10-24 Millennium Pharmaceuticals, Inc. 68723, membres de la famille des cotransporteurs de sodium/glucose et utilisations associees
ATE318272T1 (de) 2001-04-11 2006-03-15 Bristol Myers Squibb Co Aminosäurekomplexe von c-arylglycosiden zur behandlung von diabetes und verfahren
EP1389621A4 (fr) 2001-04-27 2005-05-11 Ajinomoto Kk Derives pyrazolyl-o-glycoside n-substitues et medicament contre le diabete en contenant
CA2448741C (fr) 2001-05-30 2010-06-22 Kissei Pharmaceutical Co., Ltd. Derive de glucopyranosyloxypyrazole, composition medicinale contenant celui-ci, et utilisation medicinale et intermediaire de celui-ci
EP1405859A4 (fr) 2001-06-20 2008-01-23 Kissei Pharmaceutical Derive heterocyclique azote, composition medicinale contenant ce derive, leur utilisation medicinale et intermediaire associe
JP4115105B2 (ja) 2001-07-02 2008-07-09 協和醗酵工業株式会社 ピラゾール誘導体
US7082091B2 (en) * 2001-07-31 2006-07-25 Ricoh Company, Ltd. Information reproducing method judging a multivalued level of a present cell by referring to judged multivalued levels of a preceding cell and an ensuing cell
PL210710B1 (pl) 2002-03-22 2012-02-29 Kissei Pharmaceutical Krystaliczne postaci 2-(4-metoksybenzylo) fenylo-6-O-etoksykarbonylo-ß-D-glukopiranozydu, ich zastosowanie oraz zawierająca je kompozycja farmaceutyczna
US20070059356A1 (en) 2002-05-31 2007-03-15 Almarsson Oern Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
DE10225844A1 (de) 2002-06-04 2003-12-18 Lang Florian sgk und nedd als diagnostische und therapeutische targets
DE10231370B4 (de) 2002-07-11 2006-04-06 Sanofi-Aventis Deutschland Gmbh Thiophenglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel
TWI254635B (en) 2002-08-05 2006-05-11 Yamanouchi Pharma Co Ltd Azulene derivative and salt thereof
AU2003254847B2 (en) 2002-08-08 2009-06-04 Kissei Pharmaceutical Co., Ltd. Pyrazole derivative, medicinal composition containing the same, medicinal use thereof, and intermediate for production thereof
AU2003254904A1 (en) 2002-08-09 2004-02-25 Taisho Pharmaceutical Co., Ltd. Aryl 5-thio-beta-d-glucopyranoside derivatives and therapeutic agents for diabetes containing the same
DE10237085A1 (de) 2002-08-09 2004-02-19 Bioagency Ag Verwendung von phosphororganischen Verbindungen zur therapeutischen und prophylaktischen Behandlung von Infektionen
JP2004137245A (ja) 2002-08-23 2004-05-13 Kissei Pharmaceut Co Ltd ピラゾール誘導体、それを含有する医薬組成物、その医薬用途及びその製造中間体
US20060063711A1 (en) 2002-10-29 2006-03-23 Keiji Iwamoto Use of sglt homolog
US20060035844A1 (en) 2002-12-04 2006-02-16 Fumiaki Ito Preventive or remedy for diseases caused by hyperglycemia
JP4651934B2 (ja) 2002-12-04 2011-03-16 キッセイ薬品工業株式会社 ベンジルフェノール誘導体、それを含有する医薬組成物およびその医薬用途
DE10258007B4 (de) 2002-12-12 2006-02-09 Sanofi-Aventis Deutschland Gmbh Aromatische Fluorglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel
DE10258008B4 (de) 2002-12-12 2006-02-02 Sanofi-Aventis Deutschland Gmbh Heterocyclische Fluorglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel
US7655633B2 (en) 2002-12-25 2010-02-02 Kissei Pharmaceutical Co., Ltd. Nitrogen-containing heterocyclic derivatives, medicinal compositions containing the same and medicinal use thereof
CN101260130A (zh) 2003-01-03 2008-09-10 布里斯托尔-迈尔斯斯奎布公司 制备c-芳基葡糖苷sglt2抑制剂的方法
CN1771334A (zh) 2003-03-07 2006-05-10 施瑞修德制药公司 用于确定肿瘤对抗肿瘤药剂的治疗的敏感性的方法
MXPA05009356A (es) 2003-03-14 2005-12-05 Astellas Pharma Inc Derivados de c-glicosido y sales de los mismos.
JP2004300102A (ja) 2003-03-31 2004-10-28 Kissei Pharmaceut Co Ltd 縮合複素環誘導体、それを含有する医薬組成物およびその医薬用途
WO2004089967A1 (fr) 2003-04-01 2004-10-21 Taisho Pharmaceutical Co., Ltd. Derives heteroaryle 5-thio-$g(b)-d-glucopyranoside et medicaments contre le diabete contenant ces derives
US7439232B2 (en) 2003-04-01 2008-10-21 Taisho Pharmaceutical Co., Ltd. Heteroaryl 5-thio-β-D-glucopyranoside derivatives and therapeutic agents for diabetes containing the same
AU2003902263A0 (en) 2003-05-12 2003-05-29 Fujisawa Pharmaceutical Co., Ltd. Monosaccharide compounds
WO2004106352A1 (fr) 2003-05-29 2004-12-09 Taisho Pharmaceutical Co., Ltd. Procede pour produire un intermediaire d'aldohexopyranose
JP2004359630A (ja) 2003-06-06 2004-12-24 Yamanouchi Pharmaceut Co Ltd ジフルオロジフェニルメタン誘導体及びその塩
EP1637539B1 (fr) 2003-06-20 2012-01-18 Kissei Pharmaceutical Co., Ltd. Derive de pyrazole, composition de medicaments contenant ledit derive et intermediaire de production associe
EA015104B1 (ru) 2003-08-01 2011-06-30 Мицубиси Танабе Фарма Корпорейшн Новые соединения, обладающие ингибирующей активностью в отношении натрийзависимого транспортера
UA86042C2 (en) 2003-08-01 2009-03-25 Янссен Фармацевтика Н.В. Substituted indazole-o-glucosides
US7375090B2 (en) 2003-08-26 2008-05-20 Boehringer Ingelheim International Gmbh Glucopyranosyloxy-pyrazoles, pharmaceutical compositions containing these compounds, the use thereof and processed for the preparation thereof
US7371732B2 (en) 2003-12-22 2008-05-13 Boehringer Ingelheim International Gmbh Glucopyranosyloxy-substituted aromatic compounds, medicaments containing such compounds, their use and process for their manufacture
JP2005247834A (ja) 2004-02-04 2005-09-15 Taisho Pharmaceut Co Ltd ナトリウム依存性グルコース供輸送体２の活性阻害剤
AU2005219779B2 (en) 2004-03-04 2011-04-14 Kissei Pharmaceutical Co., Ltd. Fused heterocycle derivative, medicinal composition containing the same, and medicinal use thereof
WO2005085265A1 (fr) 2004-03-04 2005-09-15 Kissei Pharmaceutical Co., Ltd. Derive heterocyclique accole, composition medicamenteuse en contenant, et son utilisation medicamenteuse
CN1950389B (zh) 2004-03-04 2011-01-19 橘生药品工业株式会社 含氮稠环衍生物，含该衍生物的药物组合物，和其作为药物的用途
DE102004012676A1 (de) * 2004-03-16 2005-10-06 Boehringer Ingelheim Pharma Gmbh & Co. Kg Glucopyranosyl-substituierte Phenyle, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
RS52365B (en) 2004-03-16 2012-12-31 Boehringer Ingelheim International Gmbh BENZOL DERIVATIVES SUBSTITUTED BY GLUCOPYRANOSIL, MEDICINAL PRODUCTS CONTAINING THESE COMPOUNDS, THEIR USE AND THE PROCEDURE FOR THEIR PRODUCTION
JPWO2005095372A1 (ja) 2004-03-31 2008-02-21 キッセイ薬品工業株式会社 ナフタレン誘導体、それを含有する医薬組成物及びその医薬用途
WO2005095373A1 (fr) 2004-03-31 2005-10-13 Kissei Pharmaceutical Co., Ltd. Dérivé naphtalénique, composition médicale le contenant et usage médical
JPWO2005095429A1 (ja) 2004-03-31 2008-02-21 キッセイ薬品工業株式会社 フェノール誘導体、それを含有する医薬組成物及びその医薬用途
DE102004028241B4 (de) 2004-06-11 2007-09-13 Sanofi-Aventis Deutschland Gmbh Neue Fluorglykosidderivate von Pyrazolen, diese Verbindungen enthaltende Arzneimittel und Herstellung dieser Arzneimittel
US7393836B2 (en) 2004-07-06 2008-07-01 Boehringer Ingelheim International Gmbh D-xylopyranosyl-substituted phenyl derivatives, medicaments containing such compounds, their use and process for their manufacture
CA2572149A1 (fr) 2004-07-08 2006-01-19 Astellas Pharma Inc. Procede de fabrication de derives d'azulene et intermediaires pour la synthese desdits derives
DE102004034690A1 (de) 2004-07-17 2006-02-02 Boehringer Ingelheim Pharma Gmbh & Co. Kg Methyliden-D-xylopyranosyl-und Oxo-D-xylopyranosyl-substituierte Phenyle, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
CA2572793C (fr) 2004-07-21 2015-11-03 Kissei Pharmaceutical Co., Ltd. Inhibiteur de la progression d'une maladie attribuee a une accumulation anormale de corps gras dans le foie
TW200606129A (en) 2004-07-26 2006-02-16 Chugai Pharmaceutical Co Ltd Novel cyclohexane derivative, its prodrug, its salt and diabetic therapeutic agent containing the same
WO2006010557A1 (fr) 2004-07-27 2006-02-02 Boehringer Ingelheim International Gmbh Cyclenes substitues par d-glucopyranosyle-phenyle, medicaments contenant lesdits composes, leur utilisation et procede de production correspondant
WO2006018150A1 (fr) 2004-08-11 2006-02-23 Boehringer Ingelheim International Gmbh Cycles a substitution d-xylopyranosyl-phenyle, medicaments contenant ces composes, leur utilisation, et leur procede de production
AR051446A1 (es) 2004-09-23 2007-01-17 Bristol Myers Squibb Co Glucosidos de c-arilo como inhibidores selectivos de transportadores de glucosa (sglt2)
JP2006117651A (ja) 2004-09-27 2006-05-11 Taisho Pharmaceut Co Ltd Ｓｇｌｔ２の活性阻害剤
CA2581922A1 (fr) 2004-09-29 2006-04-06 Kissei Pharmaceutical Co., Ltd. Compose heterocyclique azote 1-(.beta.-d-glycopyranosyl)-3-substitue, preparation therapeutique contenant ledit compose, et emploi medical dudit compose
DE102004048388A1 (de) 2004-10-01 2006-04-06 Boehringer Ingelheim Pharma Gmbh & Co. Kg D-Pyranosyl-substituierte Phenyle, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
JP5086643B2 (ja) 2004-11-18 2012-11-28 キッセイ薬品工業株式会社 １−置換−３−（β−Ｄ−グリコピラノシル）含窒素ヘテロ環化合物、及びそれを含有する医薬
JP2008007405A (ja) 2004-12-07 2008-01-17 Takeda Chem Ind Ltd カルボキサミド誘導体
ATE407938T1 (de) 2004-12-16 2008-09-15 Boehringer Ingelheim Int Glucopyranosyl-substituierte benzen-derivate, medikamente mit solchen verbindungen, ihre verwendung und herstellungsverfahren dafür
TW200637839A (en) 2005-01-07 2006-11-01 Taisho Pharmaceutical Co Ltd 1-thio-d-glucitol derivatives
TW200637869A (en) 2005-01-28 2006-11-01 Chugai Pharmaceutical Co Ltd The spiroketal derivatives and the use as therapeutical agent for diabetes of the same
AR053329A1 (es) 2005-01-31 2007-05-02 Tanabe Seiyaku Co Derivados de indol utiles como inhibidores de los transportadores de glucosa dependientes del sodio (sglt)
US7749972B2 (en) 2005-02-15 2010-07-06 Kissei Pharmaceutical Co., Ltd. 1-substituted-7-(β-D-glycopyranosyloxy)(aza)indole compound and pharmaceutical containing the same
DE602006009772D1 (de) 2005-02-23 2009-11-26 Boehringer Ingelheim Int Glucopyranosylsubstituierte ((hetero)arylethynyl-benzyl)-benzenderivative und deren verwendung als inhibitoren des natriumabhängigen glucose-cotransporters typ 2 (sglt2)
EP1877798A2 (fr) 2005-04-15 2008-01-16 Cenix Bioscience GmbH Gènes marqueurs humains et agents de diagnostic, de traitement et de prophylaxie des troubles cardio-vasculaires et de l'athérosclérose
WO2006108842A1 (fr) 2005-04-15 2006-10-19 Boehringer Ingelheim International Gmbh Derives de glucopyranosyl-substitue (heteroaryloxy-benzyl)-benzene utilises comme inhibiteurs de sglt
JPWO2006115137A1 (ja) 2005-04-22 2008-12-18 キッセイ薬品工業株式会社 ２−アミノベンズイミダゾール誘導体及びその医薬用途
US20070009615A1 (en) 2005-04-29 2007-01-11 Litao Zhong Compositions and methods for controlling glucose uptake
UA91546C2 (uk) 2005-05-03 2010-08-10 Бьорінгер Інгельхайм Інтернаціональ Гмбх КРИСТАЛІЧНА ФОРМА 1-ХЛОР-4-(β-D-ГЛЮКОПІРАНОЗ-1-ИЛ)-2-[4-((S)-ТЕТРАГІДРОФУРАН-3-ІЛОКСИ)-БЕНЗИЛ]-БЕНЗОЛУ, СПОСІБ ЇЇ ОДЕРЖАННЯ ТА ЇЇ ЗАСТОСУВАННЯ ПРИ ПРИГОТУВАННІ ЛІКАРСЬКИХ ЗАСОБІВ
US7723309B2 (en) 2005-05-03 2010-05-25 Boehringer Ingelheim International Gmbh Crystalline forms of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((R)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments
US7772191B2 (en) 2005-05-10 2010-08-10 Boehringer Ingelheim International Gmbh Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives and intermediates therein
WO2007000445A1 (fr) 2005-06-29 2007-01-04 Boehringer Ingelheim International Gmbh Derives de benzyle-benzene a substitution glucopyranosyle, medicaments contenant de tels composes, utilisation et production de ces derniers
TW200726755A (en) 2005-07-07 2007-07-16 Astellas Pharma Inc A crystalline choline salt of an azulene derivative
WO2007014894A2 (fr) 2005-07-27 2007-02-08 Boehringer Ingelheim International Gmbh Derives de ((hetero)cycloalkylethynyl-benzyl)-benzene glucopyranosyl-substitutes, medicaments contenant ces composes, leur utilisation, et procede pour les produire
US20070036874A1 (en) 2005-08-05 2007-02-15 Litao Zhong Compositions and methods for controlling glucose and lipid uptake from foods
ATE484499T1 (de) 2005-08-30 2010-10-15 Boehringer Ingelheim Int Glucopyranosyl-substituierte benzyl-derivate, medikamente mit solchen verbindungen, ihre verwendung und herstellungsverfahren dafür
BRPI0615882A2 (pt) 2005-09-08 2011-05-31 Boehringer Ingelheim Int formas cristalinas de 1-cloro-4-(beta-d-glicopiranos-1-il)-2-(4-etinil-benzil)- benzeno, métodos para sua preparação e o uso para preparar medicamentos do mesmo
US20070099237A1 (en) 2005-10-31 2007-05-03 The Regents Of The University Of Michigan Reaction co-crystallization of molecular complexes or co-crystals
TWI370818B (en) 2006-04-05 2012-08-21 Astellas Pharma Inc Cocrystal of c-glycoside derivative and l-proline
JP2009167104A (ja) 2006-05-02 2009-07-30 Taisho Pharmaceutical Co Ltd フェニル５−チオグリコシド化合物
JP2009167103A (ja) 2006-05-02 2009-07-30 Taisho Pharmaceutical Co Ltd ピラゾリル５−チオグリコシド化合物
PE20080697A1 (es) 2006-05-03 2008-08-05 Boehringer Ingelheim Int Derivados de benzonitrilo sustituidos con glucopiranosilo, composiciones farmaceuticas que contienen compuestos de este tipo, su uso y procedimiento para su fabricacion
EP2019679B1 (fr) * 2006-05-23 2018-06-20 Theracos, Inc. Inhibiteurs de transport de glucose et procédés d'utilisation
DE102006028862A1 (de) 2006-06-23 2007-12-27 Merck Patent Gmbh 3-Amino-imidazo[1,2-a]pyridinderivate
US7919598B2 (en) 2006-06-28 2011-04-05 Bristol-Myers Squibb Company Crystal structures of SGLT2 inhibitors and processes for preparing same
NZ573843A (en) 2006-06-29 2011-02-25 Taisho Pharmaceutical Co Ltd C-phenyl 1-thioglucitol compound
TWI432446B (zh) 2006-07-27 2014-04-01 Chugai Pharmaceutical Co Ltd 稠環螺酮縮醇衍生物、及其做為糖尿病治療藥之使用
TWI418556B (zh) 2006-07-27 2013-12-11 Mitsubishi Tanabe Pharma Corp 吲哚衍生物
JP2008050353A (ja) 2006-07-27 2008-03-06 Mitsubishi Tanabe Pharma Corp 医薬組成物
TWI403516B (zh) * 2006-07-27 2013-08-01 Chugai Pharmaceutical Co Ltd To replace spirocyclic alcohol derivatives, and its use as a therapeutic agent for diabetes
US20080027014A1 (en) 2006-07-28 2008-01-31 Tanabe Seiyaku Co., Ltd. Novel SGLT inhibitors
TW200817424A (en) 2006-08-04 2008-04-16 Daiichi Sankyo Co Ltd Benzylphenyl glucopyranoside derivatives
CN101121148B (zh) 2006-08-08 2010-05-12 中国科学院大连化学物理研究所 一种含分子筛的流化反应催化剂直接成型方法
JP5231416B2 (ja) * 2006-08-09 2013-07-10 ダウ グローバル テクノロジーズ エルエルシー 膨張方向が制御可能なマルチセグメント膨張性ポリマー組成物
EP2054426A1 (fr) 2006-08-15 2009-05-06 Boehringer Ingelheim International GmbH Dérivés de cyclopropyl-benzène à substitution glucopyranosyle, compositions pharmaceutiques contenant de tels composés, leur utilisation en tant qu'inhibiteurs de sglt et leur procédé de fabrication
US7858587B2 (en) 2006-09-21 2010-12-28 Boehringer Ingelheim International Gmbh Glucopyranosyl-substituted difluorobenzyl-benzene derivates, medicaments containing such compounds, their use and process for their manufacture
EP2072522A4 (fr) 2006-10-13 2010-01-06 Chugai Pharmaceutical Co Ltd Dérivé de spirocétal de thioglucose et utilisation de celui-ci comme agent thérapeutique pour le diabète
DE102006048728A1 (de) 2006-10-16 2008-04-17 Merck Patent Gmbh 3-Amino-imidazo{1,2-a]pyridinderivate
WO2008049923A1 (fr) 2006-10-27 2008-05-02 Boehringer Ingelheim International Gmbh Forme cristalline du 4-(β-d-glucopyranos-1-yl)-1-méthyl-2-[4-((s)-tétrahydrofuran-3-yloxy)benzyl]benzène, procédé pour la préparation de celle-ci et utilisation de celle-ci pour préparer des médicaments
JP2010508371A (ja) 2006-11-06 2010-03-18 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング グルコピラノシル置換フェニル誘導体、該化合物を含有する医薬品及びその使用と製造方法
WO2008115574A1 (fr) 2007-03-21 2008-09-25 Reliant Pharmaceuticals, Inc. Antagoniste cb1 et agent dyslipidémique et/ou régulateur métabolique et procédés de préparation et d'utilisation correspondants
TW200904454A (en) 2007-03-22 2009-02-01 Bristol Myers Squibb Co Methods for treating obesity employing an SGLT2 inhibitor and compositions thereof
NZ582536A (en) 2007-07-26 2012-01-12 Lexicon Pharmaceuticals Inc Methods and compounds useful for the preparation of sodium glucose co-transporter 2 inhibitors
PE20090603A1 (es) 2007-08-16 2009-06-11 Boehringer Ingelheim Int Composicion farmaceutica que comprende un inhibidor de sglt2 y un inhibidor de dpp iv
LT2187742T (lt) 2007-08-23 2018-01-10 Theracos Sub, Llc (2s,3r,4r,5s,6r)-2-(4-chlor-3-benzilfenil)-6-(hidroksimetil)tetrahidro-2h-piran-3,4,5-triolio dariniai, skirti panaudoti diabeto gydymui
CL2008003653A1 (es) 2008-01-17 2010-03-05 Mitsubishi Tanabe Pharma Corp Uso de un inhibidor de sglt derivado de glucopiranosilo y un inhibidor de dppiv seleccionado para tratar la diabetes; y composicion farmaceutica.
CN101503399B (zh) * 2008-02-04 2012-06-27 白鹭医药技术（上海）有限公司 C-芳基葡萄糖苷sglt2抑制剂

Also Published As

Publication number Publication date
CA2733795A1 (fr) 2010-03-04
PE20110288A1 (es) 2011-05-26
FR18C1036I1 (fr) 2018-10-05
CN102149717B (zh) 2014-05-14
NO2018019I1 (no) 2018-06-26
KR20110045093A (ko) 2011-05-03
EA018492B1 (ru) 2013-08-30
BRPI0918841A2 (pt) 2015-12-08
EA201100266A1 (ru) 2011-10-31
HK1156616A1 (en) 2012-06-15
CN103497199A (zh) 2014-01-08
BRPI0918841B1 (pt) 2019-10-08
RS52236B (en) 2012-10-31
HUS1800031I1 (hu) 2018-08-28
KR101446454B1 (ko) 2014-10-06
MX2011002166A (es) 2011-04-07
KR20130116078A (ko) 2013-10-22
NI201100043A (es) 2011-08-05
CN102149717A (zh) 2011-08-10
SV2011003842A (es) 2011-03-23
CO6341636A2 (es) 2011-11-21
MA32590B1 (fr) 2011-08-01
AU2009286380A1 (en) 2010-03-04
ATE540040T1 (de) 2012-01-15
LTPA2018510I1 (lt) 2018-09-25
IL236804A0 (en) 2015-03-31
JP2012500842A (ja) 2012-01-12
ES2380408T9 (es) 2013-02-22
ME01285A (me) 2013-06-20
PT2334687E (pt) 2012-04-13
KR101338540B1 (ko) 2013-12-06
AP2011005616A0 (en) 2011-04-30
MY155418A (en) 2015-10-15
ECSP11010854A (es) 2011-03-31
EP2334687B1 (fr) 2012-01-04
CN103497199B (zh) 2015-04-29
DK2334687T5 (da) 2012-09-10
AR073138A1 (es) 2010-10-13
CA2733795C (fr) 2013-12-31
NZ591027A (en) 2012-11-30
HN2009001652A (es) 2012-02-13
LTC2334687I2 (lt) 2019-09-10
WO2010023594A1 (fr) 2010-03-04
GEP20135803B (en) 2013-04-10
DOP2011000058A (es) 2011-03-15
HK1193606A1 (en) 2014-09-26
BRPI0918841B8 (pt) 2021-05-25
TWI387598B (zh) 2013-03-01
HRP20120104T1 (hr) 2012-02-29
NO2018019I2 (no) 2019-02-19
EP2334687A1 (fr) 2011-06-22
IL236804B (en) 2019-06-30
CY2018024I2 (el) 2019-11-27
PA8840801A1 (es) 2010-04-21
ES2380408T3 (es) 2012-05-11
CR20110077A (es) 2011-03-09
SI2334687T1 (sl) 2012-03-30
CY2018024I1 (el) 2019-11-27
CL2011000394A1 (es) 2011-06-17
US20100056618A1 (en) 2010-03-04
AU2009286380A8 (en) 2011-03-17
IL211226A (en) 2015-02-26
ZA201101341B (en) 2011-11-30
JP4825322B1 (ja) 2011-11-30
PL2334687T3 (pl) 2012-05-31
AU2009286380B2 (en) 2011-09-15
DK2334687T3 (da) 2012-04-16
UY32073A (es) 2010-03-26
EP2334687B9 (fr) 2012-08-08
AP2728A (en) 2013-08-31
TW201014863A (en) 2010-04-16
NL300943I2 (nl) 2018-08-07
CY1112497T1 (el) 2015-12-09
IL211226A0 (en) 2011-04-28
US8080580B2 (en) 2011-12-20

Similar Documents

Publication Publication Date Title
FR18C1036I2 (fr) Derives de dioxa-bicyclo[3.2.1.]octane-2,3,4-triol
HRP20150107T1 (en) Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives
ATE555107T1 (de) 2-aza-bicyclo-ä2,2,1-üheptan-derivate
BR112012003704A2 (pt) derivados de 3-amino-5-fenil-5,6-di-hidro-2h[1,4]oxazina
BRPI0811718A2 (pt) Derivados de 3,3-espiroindolinona
IL206765A0 (en) 4,5-dihydro-oxazol-2-yl-amine derivatives
DOP2007000080A (es) Piridin [3,4-b] pirazinonas
BRPI0917446A2 (pt) derivados de acilaminobenzamida.
BRPI0916363A2 (pt) derivados de 4,5-di-hidro-oxazol-2-ila
BRPI0906714A2 (pt) Derivados de oxazepinopirimidona heteroarilamida substituídos.
BRPI0815059A2 (pt) Derivado de 1,3-di-hidroisoindol
BRPI0816679A2 (pt) Derivados de ftalazinona.
BRPI0920543A2 (pt) Derivados de biciclootano-1,3-diona substituídos com fenila
BRPI0907749A2 (pt) Derivados de 3,8-diaminotetrahidroquinolina
BRPI0911622A2 (pt) derivados de benzoxepina e benzociclo-heptano.
BRPI1011720A2 (pt) compostos de 1,1,1- tri-flúor-2 hidróxi-propila.
BRPI0918503A2 (pt) processo de preparação da 1,6:2,3-dianidro-beta-d-manopiranose
NL2003137A1 (nl) Landbouwmachine.
NL2003140A1 (nl) Landbouwmachine.
TH0901003856A (th) อนุพันธ์ของ ไดออกซา-ไบไซโคล[3.2.1]ออคเทน-2,3,4-ไทรออล
ITPO20080016A1 (it) Tricoceutica, prodotto tricoceutico.